Funding
Activaero GmbH, which specialises in controlled breathing technologies for inhaled therapeutic agents, has announced the closing of a first round financing of €10.7 million led by BioMedPartners AG, and including VI Partners AG, Abalis Finance AG and Vesalius Biocapital I.
The financing enables the company to further develop its inhalation devices and strengthen business development activities.
“Securing venture capital support for Activaero is important for our strategy to further increase visibility and awareness within the pharmaceutical industry,” said Gerhard Scheuch, Chief Executive Officer of Activaero. “The development and commercialisation of our products and technology is now securely funded going forward.”
Gerhard Ries of BioMedPartners, Arnd Kaltofen of VI Partners, Jean-Marie Luechinger of Abalis Finance, Christian Schneider of Vesalius Biocapital Partners and John Patton, founder of Nektar Therapeutics, have all joined Activaero’s board.
Activaero’s technologies allow for precise and efficient patient-tailored pulmonary delivery. The company has two products on the market, Akita, a patient-tailored controlled breathing system with a smartcard that records the patient dosing parameters, and Watchhaler, a hand-held delivery system tailored for children.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
